Female Friends

Mucommune

Advancing Innovations to Promote Female Reproductive Health

  • First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health

  • Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules

  • Unparalleled safety from topical delivery

Latest News

Our lead contraceptive mAb candidate is published in Science Translational MedicineUNC Chapel Hill Press release.  Media coverage:
The Scientist, Wired Magazine, MedScape, WRAL TechWire.

Inhalon, our sister company, announces partnership with Celltrion and initiates Phase 1 and 2 clinical trial.

March 11th, 2021 -
 Mucommune in consortium that initiates first-ever clinical trial for a contraceptive mAb (ClinicalTrials.gov, NCT04731818).